Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $478000.0.

  • Mirum Pharmaceuticals' Gains from Investment Securities fell 3514.25% to $478000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 7773.75%. This contributed to the annual value of $9.6 million for FY2024, which is 81394.69% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $478000.0 for Q3 2025, which was down 3514.25% from $1.3 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $9.2 million during Q2 2024, with a 5-year trough of -$1.1 million in Q4 2021.
  • For the 5-year period, Mirum Pharmaceuticals' Gains from Investment Securities averaged around $2.4 million, with its median value being $417000.0 (2025).
  • Examining YoY changes over the last 5 years, Mirum Pharmaceuticals' Gains from Investment Securities showed a top increase of 1415903.62% in 2021 and a maximum decrease of 46666.67% in 2021.
  • Mirum Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$1.1 million in 2021, then soared by 391.64% to $3.2 million in 2022, then plummeted by 99.1% to $29000.0 in 2023, then surged by 2441.38% to $737000.0 in 2024, then plummeted by 35.14% to $478000.0 in 2025.
  • Its last three reported values are $478000.0 in Q3 2025, $1.3 million for Q2 2025, and $356000.0 during Q1 2025.